234 related articles for article (PubMed ID: 25115434)
1. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K
Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
Kobayashi M; Kajiwara M; Hasegawa S
J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
[TBL] [Abstract][Full Text] [Related]
6. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
8. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
Karaźniewicz-Łada M; Danielak D; Rubiś B; Burchardt P; Oszkinis G; Główka F
J Clin Pharmacol; 2014 Aug; 54(8):874-80. PubMed ID: 24782221
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study.
Collet JP; Funck-Brentano C; Prats J; Salem JE; Hulot JS; Guilloux E; Hu MY; He K; Silvain J; Gallois V; Brugier D; Anzaha G; Galier S; Nicolas N; Montalescot G
Am J Cardiovasc Drugs; 2016 Feb; 16(1):43-53. PubMed ID: 26386578
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
Kim HS; Lim Y; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
Br J Clin Pharmacol; 2016 Feb; 81(2):301-12. PubMed ID: 26426352
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.
Song BL; Wan M; Tang D; Sun C; Zhu YB; Linda N; Fan HW; Zou JJ
Clin Ther; 2018 Jul; 40(7):1170-1178. PubMed ID: 30017169
[TBL] [Abstract][Full Text] [Related]
15. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
16. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ; Tantry US; Gurbel PA
Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
[TBL] [Abstract][Full Text] [Related]
17. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
18. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.
Nooney VB; Hurst NL; Chirkov YY; De Caterina R; Horowitz JD
Vascul Pharmacol; 2015; 65-66():17-22. PubMed ID: 25460367
[TBL] [Abstract][Full Text] [Related]
19. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
[TBL] [Abstract][Full Text] [Related]
20. The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration.
Kim HS; Cho DY; Park BM; Bae SK; Yoon YJ; Oh M; Ghim JL; Kim EY; Kim DH; Shin JG
J Clin Pharmacol; 2014 Aug; 54(8):850-7. PubMed ID: 24214141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
